Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a
combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine
(XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use
disorder (CUD).